



ABN 53 075 582 740

**ASX ANNOUNCEMENT**  
**8 April 2021**

---

## **Change of Company Secretary**

Bionomics Limited (ASX: BNO) (**Bionomics** or **Company**) is pleased to announce the appointment of Ms Suzanne Irwin as Company Secretary for the Company, effective immediately.

Mr Adrian Hinton, Acting Chief Financial Officer, has resigned as Interim Company Secretary, having stepped in temporarily after the loss of Mr Jack Moschakis as announced to the ASX on 24 March 2021.

Suzanne is a Fellow of the Governance Institute of Australia with over 13 years' Corporate Secretariat & company secretarial experience with ERM Power Limited (ASX300), which listed in 2010 until delisting on acquisition by Shell Energy Australia in 2019, and more recently, Company Secretary for the Queensland resources company EQ Resources Ltd (ASX:EQR) up to February 2021.

Prior to this, having completed CPA certification, Suzanne has over 15 years' financial experience in business and commercial analyst roles at various BHP mining and minerals extraction operations.

For the purposes of ASX Listing Rule 12.6 Ms Suzanne Irwin, along with Mr Adrian Hinton, will be the persons responsible for communications between the Company and ASX.

Released on authority of the Board.

### **FOR FURTHER INFORMATION PLEASE CONTACT:**

Ms Suzanne Irwin  
Company Secretary  
Bionomics Limited  
+61 417 434 457  
[Cosec@bionomics.com.au](mailto:Cosec@bionomics.com.au)

### **About Bionomics Limited**

Bionomics Limited (ASX:BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics' lead drug candidate BNC210, currently in development for initiation of a second Phase 2 trial for the treatment of PTSD, is a novel, proprietary negative allosteric modulator of the alpha-7 nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease.

[www.bionomics.com.au](http://www.bionomics.com.au)